Showing results (1-10 of 376) with videos related to
Sort By:
Pageof 38
European Heart Journal|January 14, 2011
Cardiovascular implications from untreated human immunodeficiency virus infectionJason V Baker, Jens D LundgrenAIDS (London, England)|September 29, 2012
Platelet count kinetics following interruption of antiretroviral treatmentEva Zetterberg, Jacqueline Neuhaus, Jason V Baker, et al.The Journal of Infectious Diseases|December 16, 2017
Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) StudyAndreas Ronit, Shweta Sharma, Jason V Baker, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2019
Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) TrialJeffrey A Boatman, Jason V Baker, Sean Emery, et al.Current Opinion in Infectious Diseases|April 20, 2004
Clinical trial methodology and clinical cohorts: the importance of complete follow-up in trials evaluating the virological efficacy of anti-HIV medicinesOle Kirk, Jens D LundgrenClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 29, 2003
Anemia and survival in human immunodeficiency virusJens D Lundgren, Amanda MocroftThe Journal of Antimicrobial Chemotherapy|May 28, 2004
Starting highly active antiretroviral therapy: why, when and response to HAARTAmanda Mocroft, Jens D LundgrenBest Practice & Research. Clinical Endocrinology & Metabolism|June 14, 2011
The metabolic syndrome in HIVSigne W Worm, Jens D LundgrenCurrent Opinion in HIV and AIDS|April 18, 2009
Guidelines for managing cardiovascular risk: an evolving areaJudith S Currier, Jens D LundgrenCritical Care (London, England)|February 8, 2008
Procalcitonin in liver transplant patients--yet another stone turnedJens-Ulrik Jensen, Jens D LundgrenPageof 38